Halozyme strikes global deal with Vertex to expand Hypercon drug delivery technology
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
ShunzymeX leverages a proprietary protease to streamline purification
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Developing basic technology for personalized medicine: Dr. Paidi Yella Reddy, Sapala Organics
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Subscribe To Our Newsletter & Stay Updated